- Home
- ZYME vs PDT Comparison
ZYME vs PDT Comparison
Compare ZYME & PDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- PDT
- Stock Information
- Founded
- ZYME 2003
- PDT 1989
- Country
- ZYME United States
- PDT United States
- Employees
- ZYME N/A
- PDT N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- PDT Finance Companies
- Sector
- ZYME Health Care
- PDT Finance
- Exchange
- ZYME Nasdaq
- PDT Nasdaq
- Market Cap
- ZYME 751.6M
- PDT 648.3M
- IPO Year
- ZYME 2017
- PDT N/A
- Fundamental
- Price
- ZYME $15.39
- PDT $12.69
- Analyst Decision
- ZYME Buy
- PDT
- Analyst Count
- ZYME 5
- PDT 0
- Target Price
- ZYME $19.00
- PDT N/A
- AVG Volume (30 Days)
- ZYME 572.6K
- PDT 145.6K
- Earning Date
- ZYME 10-31-2024
- PDT 01-01-0001
- Dividend Yield
- ZYME N/A
- PDT 8.88%
- EPS Growth
- ZYME N/A
- PDT N/A
- EPS
- ZYME N/A
- PDT N/A
- Revenue
- ZYME $62,199,000.00
- PDT N/A
- Revenue This Year
- ZYME $30.09
- PDT N/A
- Revenue Next Year
- ZYME N/A
- PDT N/A
- P/E Ratio
- ZYME N/A
- PDT N/A
- Revenue Growth
- ZYME N/A
- PDT N/A
- 52 Week Low
- ZYME $7.80
- PDT $8.77
- 52 Week High
- ZYME $17.70
- PDT $13.05
- Technical
- Relative Strength Index (RSI)
- ZYME 55.74
- PDT 40.22
- Support Level
- ZYME $12.39
- PDT $12.70
- Resistance Level
- ZYME $17.70
- PDT $13.24
- Average True Range (ATR)
- ZYME 0.84
- PDT 0.23
- MACD
- ZYME 0.10
- PDT -0.02
- Stochastic Oscillator
- ZYME 56.50
- PDT 16.67
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About PDT John Hancock Premium Dividend Fund
John Hancock Premium Div Fund II is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest growth of capital. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, and short-term investments.